Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор

DRUG3 trials

Sponsors

Iovance Biotherapeutics Inc.

Conditions

MelanomaMetastatic Non-Small-Cell Lung CancerNeoplasm

Phase 2

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

RecruitingCTIS2024-510778-26-00

Iovance Biotherapeutics Inc.Metastatic Non-Small-Cell Lung Cancer

Start: 2025-12-19Target: 115Updated: 2025-11-26

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors

Active, not recruitingCTIS2024-510779-39-00

Iovance Biotherapeutics Inc.Neoplasm

Start: 2018-12-19Target: 95Updated: 2026-01-21

Phase 3

A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma

RecruitingCTIS2022-503140-41-00

Iovance Biotherapeutics Inc.Melanoma

Start: 2024-11-29Target: 280Updated: 2025-10-31